1. 1711. In Vitro Activity of Cefiderocol Against US Achromobacter spp. and Burkholderia spp. Clinical Isolates from the SENTRY Surveillance Program 2020-2021. (15th December 2022) Authors: Takemura, Miki; Shortridge, Dee; Slover, Christine M; Longshaw, Christopher M; Echols, Roger; Echols, Roger; Echols, Roger; Yamano, Yoshinori Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. 1715. In Vitro Antibacterial Activity of Cefiderocol against Difficult-to-treat Resistant (DTR) Gram-negative Pathogens in United States from SENTRY Antimicrobial Surveillance Program in 2020/2021. (15th December 2022) Authors: Yamano, Yoshinori; Takemura, Miki; Shortridge, Dee; Slover, Christine M; Longshaw, Christopher M; Echols, Roger; Echols, Roger; Echols, Roger Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. 609. In vivo efficacy of human simulated exposures of cefiderocol (FDC) in combination with ceftazidime/avibactam (CZA) or meropenem (MEM) using in a 72 hour murine thigh infection model. (15th December 2022) Authors: Gill, Christian M; Santini, Debora; Takemura, Miki; Longshaw, Christopher M; Yamano, Yoshinori; Echols, Roger; Echols, Roger; Echols, Roger; Nicolau, David P Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. 660. In vitro activity of cefiderocol against difficult-to-treat resistance European Gram-negative bacterial pathogens from the multi-national sentinel surveillance study, SENTRY in 2020 and 2021. (15th December 2022) Authors: Santerre Henriksen, Anne Laurence; Longshaw, Christopher M; Shortridge, Dee; Streit, Jennifer M; Takemura, Miki; Yamano, Yoshinori Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. 677. Systematic Review of the Early Use Experince of Cefiderocol in Real World Practice. (15th December 2022) Authors: Viale, Pierluigi; Tascini, Carlo; Dinh, Aurelien; Longshaw, Christopher M; Fitzgerald, Anita C; Wood, Hannah; Patterson, Jacoby Vivien M; Watkins, Deborah; Wilson, Katy; Gill, Karan Journal: Open forum infectious diseases Issue: Volume 9:(2022)Supplement 2 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Comment on: Bacteraemia with an MBL-producing Klebsiella pneumoniae: treatment and the potential role of cefiderocol heteroresistance. (16th August 2022) Authors: Longshaw, Christopher M; Santerre Henriksen, Anne; Slover, Christine; Yamano, Yoshinori; Karas, J Andreas Journal: Journal of antimicrobial chemotherapy Issue: Volume 77:Number 10(2022) Page Start: 2895 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗